UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) | (Zip Code) |
(
Registrant's telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 2.02 Results of Operations and Financial Condition
On January 10, 2021, Ekso Bionics Holdings, Inc. (the “Company”) issued a press release (the “Press Release”) announcing certain preliminary financial results for the quarter and year ended December 31, 2021.
The full text of the Press Release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 2.02 of this Current Report on Form 8-K, including the information contained in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits
(d) | Exhibits |
Exhibit | Description | |
99.1 | Press Release dated January 10, 2022 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EKSO BIONICS HOLDINGS, INC. | ||
By: | /s/ John F. Glenn | |
Name: | John F. Glenn | |
Title: | Chief Financial Officer | |
Dated: January 10, 2022 |
Exhibit 99.1
Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2021 Financial Results
Company Achieves Record Quarterly Revenue of $3.9 million to $4.1 million1
RICHMOND, Calif., January 10, 2022 -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2021.
Total revenue for the fourth quarter of 2021 is an estimated range of $3.9 million to $4.1 million, reflecting year-over-year growth of 77% at the midpoint of the range, compared to total revenue of $2.3 million in the fourth quarter of 2020.
Total revenue for fiscal year 2021 is an estimated range of $11.1 million to $11.3 million, compared to $8.9 million in 2020. This reflects estimated year-over-year growth of 26% at the midpoint of the range.
Cash on hand at December 31, 2021 was $40.4 million, compared to $12.9 million at December 31, 2020.
“Our strong estimated fourth quarter 2021 revenue reflects continued momentum of our progress with leading inpatient rehabilitation operators across all regions and increased industrial orders,” commented Jack Peurach, President and Chief Executive Officer of Ekso Bionics. “As we continue to gain traction with network operators, we remain intensely focused on delivering on our key value drivers while raising awareness of the game-changing benefits that EksoNR can bring to patients. Within our industrial segment, we are expanding EVO sales by growing our pipeline and capturing new customers across a diverse segment of verticals. In spite of recent challenges, we are well-positioned for 2022 with the steadfast commitment of bringing innovative solutions to patients and workers.”
The anticipated results discussed in this press release are based on management’s preliminary, unaudited analysis of financial results for the three months and year ended December 31, 2021. As of the date of this press release, the Company has not completed its financial statement reporting process for the three months and year ended December 31, 2021, and the Company’s independent registered accounting firm has not audited the preliminary financial data discussed in this press release. During the course of the Company’s quarter- and year-end closing procedures and review process, the Company may identify items that would require it to make adjustments, which may be material to the information presented above. As a result, the estimates above constitute forward-looking information and are subject to risks and uncertainties, including possible adjustments to preliminary operating results. The Company expects to report complete fourth quarter and full year 2021 financial results during the last week of February 2022.
1 Record revenue in the fourth quarter of 2021 excludes the comparison to the first quarter of 2016, which included a one-time adjustment of $6.5 million as a result of a change in the Company’s revenue recognition policy.
1
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com or follow @EksoBionics on Twitter.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the plans, objectives and expectations of management with respect to the Company’s reporting of complete fourth quarter and full year 2021 financial results, the Company’s sales, marketing and other commercial strategies, the benefits of the Company’s products to patients and workers, future revenues or other financial results and the assumptions underlying or relating to the foregoing. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, changes resulting from the Company’s finalization of its financial statements for and as of the period and year ended December 31, 2021, information or new changes in facts or circumstances that may occur prior to the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 that are required to be included in such report, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance the Company’s technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of the Company’s sales and marketing efforts or of partners to market the Company’s products effectively, adverse results in future clinical studies of the Company's medical device products, the failure of the Company to obtain or maintain patent protection for the Company's technology, the failure of the Company to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, disruptions in the Company’s supply chain due to the ongoing COVID-19 pandemic, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit the Company’s website at www.eksobionics.com or refer to the Company’s Twitter page at @EksoBionics. The Company does not undertake to update these forward-looking statements.
Contact:
David Carey
212-867-1768
investors@eksobionics.com
2
Cover |
Jan. 10, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jan. 10, 2022 |
Entity File Number | 001-37854 |
Entity Registrant Name | Ekso Bionics Holdings, Inc. |
Entity Central Index Key | 0001549084 |
Entity Tax Identification Number | 99-0367049 |
Entity Incorporation, State or Country Code | NV |
Entity Address, Address Line One | 1414 Harbour Way South |
Entity Address, Address Line Two | Suite 1201 |
Entity Address, City or Town | Richmond |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94804 |
City Area Code | 510 |
Local Phone Number | 984-1761 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.001 par value per share |
Trading Symbol | EKSO |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
-8?20$3;8T.P6BP^0"X99K>]9!:G
'DP$YF6: DYVS;G 9+OY?-X-]O-BG!+ =L25WQ YC079GH0/ "F3 Z4#$D=4D)OM:_O*M!<
M/@@)%LF4N:7 ;K))0E,3$ U68P 1!VWQ7*HW*F:BE>(XG=.8['XB>[!L+9U;
M+@";33 ,44!DV)T!:)1B5*B1D'N#XXXG&\SWBR3JZ3;:0K=X0$:;?)BJ@ !
MK &$E&JTF,]\]RI+O)O' MCD(5'/E_>0 NK= M-CN\D-( X(GVZ' $4B"#6C
M?,,TIQ'CSZSVN,2,;45CN)^Q&!ZQ]$2Y!6M0$9IX=88$!-D0GP!JC= /ZID6
MQ.3 &P^49M)7!P.8'<'( 2//[$Y6#Q Q'[$'Z3L
M@)/=)GQ,QZ&&9@OJ8;'M'@8V\-"F32!=@)!)]66LH^E$]61+A#00B%BFS3?A
M@<8[@OA.N QT+3JPF %Z*QR6M#^'D:4T1-_H$9%TG)
MC^&\G&AWIX]5".2$@>80<8=YF9*XI@A=B-DYX$$=1%6Z=PJ3P^UZ)V=F;T?H
M0++#[2\P4"R[BWY[
%6V!?$
MZ)A5)*R8:DXB3?# 47D!J4YS417:<9 L%55L NH9HQ"@JE:JN3)F6-A*$_Y,
M5F;HQ).-@*D<&)?*RC$GM*.C0)?4(^&IF-L;R02HK*D=,ZV#$*M#%H6THT"P
M+\/MKV9D*R"N"U]%A(HL0?ZJ*^]B !'YI2 /)K